

## NON-HODGKIN LYMPHOMA

*Includes follicular, non-follicular and mature T/NK-cell lymphomas.*

### Background

This case definition was developed by the Armed Forces Health Surveillance Division (AFHSD) for the purpose of descriptive epidemiological reports on invasive cancers among active duty Service members.<sup>1</sup> The case definition uses the “standard” AFHSD oncology case definition.

### Clinical Description

Non-Hodgkin lymphomas (NHL) are a large group of cancers of white blood cells. These cancers can occur at any age and are usually characterized by swollen lymph nodes, fever, and weight loss.<sup>2</sup> There are many different types of NHL, typically defined as aggressive or indolent and originating from either B-cells or T-cells. Risk of developing NHL is elevated in persons who receive immune suppressants to prevent organ transplant rejection, people with severe autoimmune conditions, and people infected with human immunodeficiency virus (HIV) and human T-cell leukemia virus type I. Epstein Barr virus causes Burkitt lymphoma and is associated with several autoimmune-related NHLs.<sup>3</sup> Prognosis and treatment depend on the stage and type of NHL disease.

#### Case Definition and Incidence Rules (2012 - present)

For surveillance purposes, a case of non-Hodgkin lymphoma is defined as:

- *One hospitalization* with a case defining diagnosis of non-Hodgkin lymphoma (see ICD9 and ICD10 code lists below) in the *first* diagnostic position; or
- *One hospitalization with a procedure code* indicating radiotherapy, chemotherapy, or immunotherapy treatment (see ICD9 and ICD10 code lists below) in the *first* diagnostic position; AND a case defining diagnosis of non-Hodgkin lymphoma (see ICD9 and ICD10 code lists below) in the *second* diagnostic position; or
- *Three or more outpatient medical encounters*, occurring within a 90-day period, with a case defining diagnosis of non-Hodgkin lymphoma (see ICD9 and ICD10 code list below) in the *first or second* diagnostic position.

#### Incidence rules:

For individuals who meet the case definition:

- The incidence date is considered the date of the first hospitalization or outpatient medical encounter that includes a case defining diagnosis of non-Hodgkin lymphoma.

*(continued on next page)*

<sup>1</sup> Armed Forces Health Surveillance Center. Incident diagnoses of cancers and cancer-related deaths, active component, U.S. Armed Forces, 2005-2014. *MSMR* 2016; July; 23(7): 23-31.

<sup>2</sup> Non-Hodgkin Lymphoma. National Cancer Institute. Available at: <https://www.cancer.gov/types/lymphoma>. Accessed March 2025.

<sup>3</sup> American Cancer Society. Cancer Facts & Figures 2024. Available at: <https://www.cancer.org/research/cancer-facts-statistics.html>. Accessed March 2025.



### Case Definition and Incidence Rules *(continued)*

- An individual is considered an incident case *once per lifetime*.

#### Exclusions:

- None

### Codes

The following ICD9 and ICD10 codes are included in the case definition:

Condition	ICD-10-CM Codes	ICD-9-CM Codes
Follicular lymphoma	<i>C82 (follicular lymphoma)</i>	<i>202 (other malignant neoplasms of lymphoid and histiocytic tissue)</i>
	<i>C82.0 (follicular lymphoma grade I...)</i>	<i>202.0 (nodular lymphoma ...)</i>
	- C82.00 (unspecified site)	- 202.00 (unspecified site, extranodal and solid organ sites.)
	- C82.01 (lymph nodes of head, face and neck)	- 202.01 (lymph nodes of head, face and neck)
	- C82.02 (intrathoracic lymph nodes)	- 202.02 (intrathoracic lymph nodes)
	- C82.03 (intra-abdominal lymph nodes)	- 202.03 (intra-abdominal lymph nodes)
	- C82.04 (lymph nodes of axilla and upper limb)	- 202.04 (lymph nodes of axilla and upper limb)
	- C82.05 (lymph nodes of inguinal region and lower limb)	- 202.05 (lymph nodes of inguinal region and lower limb)
	- C82.06 (intrapelvic lymph nodes)	- 202.06 (intrapelvic lymph nodes)
	- C82.07 (spleen)	- 202.07 (spleen)
	- C82.08 (lymph nodes of multiple sites)	- 202.08 (lymph nodes of multiple sites)
	- C82.09 (extranodal and solid organ sites)	- 202.00 (above)
	- C82.0A (in remission); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>
	<i>C82.1 (follicular lymphoma grade II...)</i>	202.0[0-8] (above)
	- C82.10 (unspecified site)	
	- C82.11 (lymph nodes of head, face and neck)	
	- C82.12 (intrathoracic lymph nodes)	



- C82.13 (intra-abdominal lymph nodes)	
- C82.14 (lymph nodes of axilla and upper limb)	
- C82.15 (lymph nodes of inguinal region and lower limb)	
- C82.16 (intrapelvic lymph nodes)	
- C82.17 (spleen)	
- C82.18 (lymph nodes of multiple sites)	
- C82.19 (extranodal and solid organ sites)	
- C82.1A (in remission); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>
<i>C82.2 (follicular lymphoma grade III...)</i>	202.0[0-8] (above)
- C82.20 (unspecified site)	
- C82.21 (lymph nodes of head, face and neck)	
- C82.22 (intrathoracic lymph nodes)	
- C82.23 (intra-abdominal lymph nodes)	
- C82.24 (lymph nodes of axilla and upper limb)	
- C82.25 (lymph nodes of inguinal region and lower limb)	
- C82.26 (intrapelvic lymph nodes)	
- C82.27 (spleen)	
- C82.28 (lymph nodes of multiple sites)	
- C82.29 (extranodal and solid organ sites)	
- C82.2A (in remission); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>
<i>C82.3 (follicular lymphoma grade IIIa...)</i>	202.0[0-8] (above)
- C82.30 (unspecified site)	
- C82.31 (lymph nodes of head, face and neck)	
- C82.32 (intrathoracic lymph nodes)	
- C82.33 (intra-abdominal lymph nodes)	
- C82.34 (lymph nodes of axilla and upper limb)	
- C82.35 (lymph nodes of inguinal region and lower limb)	

- C82.36 (intrapelvic lymph nodes)	
- C82.37 (spleen)	
- C82.38 (lymph nodes of multiple sites)	
- C82.39 (extranodal and solid organ sites)	
- C82.3A (in remission); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>
<i>C82.4 (follicular lymphoma grade IIIb...)</i>	202.0[0-8] (above)
- C82.40 (unspecified site)	
- C82.41 (lymph nodes of head, face and neck)	
- C82.42 (intrathoracic lymph nodes)	
- C82.43 (intra-abdominal lymph nodes)	
- C82.44 (lymph nodes of axilla and upper limb)	
- C82.45 (lymph nodes of inguinal region and lower limb)	
- C82.46 (intrapelvic lymph nodes)	
- C82.47 (spleen)	
- C82.48 (lymph nodes of multiple sites)	
- C82.49 (extranodal and solid organ sites)	
- C82.4A (in remission); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>
<i>C82.5 (diffuse follicular center lymphoma...)</i>	202.8 (other malignant lymphomas...)
- C82.50 (unspecified site)	- 202.80 (unspecified site, extranodal and solid organ sites)
- C82.51 (lymph nodes of head, face and neck)	- 202.81 (lymph nodes of head, face and neck)
- C82.52 (intrathoracic lymph nodes)	- 202.82 (intrathoracic lymph nodes)
- C82.53 (intra-abdominal lymph nodes)	- 202.83 (intra-abdominal lymph nodes)
- C82.54 (lymph nodes of axilla and upper limb)	- 202.84 (lymph nodes of axilla and upper limb)
- C82.55 (lymph nodes of inguinal region and lower limb)	- 202.85 (lymph nodes of inguinal region and lower limb)
- C82.56 (intrapelvic lymph nodes)	- 202.86 (intrapelvic lymph nodes)
- C82.57 (spleen)	- 202.87 (spleen)
- C82.58 (lymph nodes of multiple sites)	- 202.88 (lymph nodes of multiple sites)

- C82.59 (extranodal and solid organ sites)	- 202.80 (above)
- C82.5A (in remission); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>
<i>C82.6 (cutaneous follicular center lymphoma...)</i>	202.0[0-8] (above)
- C82.60 (unspecified site)	
- C82.61 (lymph nodes of head, face and neck)	
- C82.62 (intrathoracic lymph nodes)	
- C82.63 (intra-abdominal lymph nodes)	
- C82.64 (lymph nodes of axilla and upper limb)	
- C82.65 (lymph nodes of inguinal region and lower limb)	
- C82.66 (intrapelvic lymph nodes)	
- C82.67 (spleen)	
- C82.68 (lymph nodes of multiple sites)	
- C82.69 (extranodal and solid organ sites)	
- C82.6A (in remission); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>
<i>C82.8 (other types of follicular center lymphoma...)</i>	202.0[0-8] (above)
- C82.80 (unspecified site)	
- C82.81 (lymph nodes of head, face and neck)	
- C82.82 (intrathoracic lymph nodes)	
- C82.83 (intra-abdominal lymph nodes)	
- C82.84 (lymph nodes of axilla and upper limb)	
- C82.85 (lymph nodes of inguinal region and lower limb)	
- C82.86 (intrapelvic lymph nodes)	
- C82.87 (spleen)	
- C82.88 (lymph nodes of multiple sites)	
- C82.89 (extranodal and solid organ sites)	
- C82.8A (in remission); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>

	<i>C82.9 (follicular lymphoma, unspecified...)</i>	202.0[0-8] (above)
	- C82.90 (unspecified site)	
	- C82.91 (lymph nodes of head, face and neck)	
	- C82.92 (intrathoracic lymph nodes)	
	- C82.93 (intra-abdominal lymph nodes)	
	- C82.94 (lymph nodes of axilla and upper limb)	
	- C82.95 (lymph nodes of inguinal region and lower limb)	
	- C82.96 (intrapelvic lymph nodes)	
	- C82.97 (spleen)	
	- C82.98 (lymph nodes of multiple sites)	
	- C82.99 (extranodal and solid organ sites)	
	- C82.9A (in remission); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>
Non-follicular lymphomas	<i>C83 (non-follicular lymphoma)</i>	<i>200 (lymphosarcoma and reticulosarcoma, and other specified malignant tumors of lymphatic tissue)</i>
	<i>C83.0 (small cell B-cell lymphoma...)</i>	<i>200.8 (other named variants of lymphosarcoma and reticulosarcoma...)</i>
	- C83.00 (unspecified site)	- 200.80 (unspecified site, extranodal and solid organ sites)
	- C83.01 (lymph nodes of head, face and neck)	- 200.81 (lymph nodes of head, face and neck)
	- C83.02 (intrathoracic lymph nodes)	- 200.82 (intrathoracic lymph nodes)
	- C83.03 (intra-abdominal lymph nodes)	- 200.83 (intra-abdominal lymph nodes)
	- C83.04 (lymph nodes of axilla and upper limb)	- 200.84 (lymph nodes of axilla and upper limb)
	- C83.05 (lymph nodes of inguinal region and lower limb)	- 200.85 (lymph nodes of inguinal region and lower limb)
	- C83.06 (intrapelvic lymph nodes)	- 200.86 (intrapelvic lymph nodes)
	- C83.07 (spleen)	- 200.87 (spleen)
	- C83.08 (lymph nodes of multiple sites)	- 200.88 (lymph nodes of multiple sites)
	- C83.09 (extranodal and solid organ sites)	- 200.80 (above)
	- C83.0A (in remission); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>
	<i>C83.1 (mantle cell lymphoma...)</i>	<i>200.4 (mantle cell lymphoma...)</i>

- C83.10 (unspecified site, extranodal and solid organ sites)	- 200.40 (unspecified site, extranodal and solid organ sites)
- C83.11 (lymph nodes of head, face and neck)	- 200.41 (lymph nodes of head, face and neck)
- C83.12 (intrathoracic lymph nodes)	- 200.42 (intrathoracic lymph nodes)
- C83.13 (intra-abdominal lymph nodes)	- 200.43 (intra-abdominal lymph nodes)
- C83.14 (lymph nodes of axilla and upper limb)	- 200.44 (lymph nodes of axilla and upper limb)
- C83.15 (lymph nodes of inguinal region and lower limb)	- 200.45 (lymph nodes of inguinal region and lower limb)
- C83.16 (intrapelvic lymph nodes)	- 200.46 (intrapelvic lymph nodes)
- C83.17 (spleen)	- 200.47 (spleen)
- C83.18 (lymph nodes of multiple sites)	- 200.48 (lymph nodes of multiple sites)
- C83.19 (extranodal and solid organ site)	
- C83.1A (in remission); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>
<i>C83.3 (diffuse large B-cell lymphoma...)</i>	<i>200.0 (reticulosarcoma...)</i> <i>200.7 (large cell lymphoma...)</i>
- C83.30 (unspecified site, extranodal and solid organ sites)	- 200.00 (unspecified site, extranodal and solid organ sites) - 200.70 (unspecified site, extranodal and solid organ sites)
- C83.31 (lymph nodes of head, face and neck)	- 200.01 (lymph nodes of head, face and neck) - 200.71 (lymph nodes of head, face and neck)
- C83.32 (intrathoracic lymph nodes)	- 200.02 (intrathoracic lymph nodes) - 200.72 (intrathoracic lymph nodes)
- C83.33 (intra-abdominal lymph nodes)	- 200.03 (intra-abdominal lymph nodes) - 200.73 (intra-abdominal lymph nodes)
- C83.34 (lymph nodes of axilla and upper limb)	- 200.04 (lymph nodes of axilla and upper limb) - 200.74 (lymph nodes of axilla and upper limb)
- C83.35 (lymph nodes of inguinal region and lower limb)	- 200.05 (lymph nodes of inguinal region and lower limb) - 200.75 (lymph nodes of inguinal region and lower limb)

- C83.36 (intrapelvic lymph nodes)	- 200.06 (intrapelvic lymph nodes) - 200.76 (intrapelvic lymph nodes)
- C83.37 (spleen)	- 200.07 (spleen) - 200.77 (spleen)
- C83.38 (lymph nodes of multiple sites)	- 200.08 (lymph nodes of multiple sites) - 200.78 (lymph nodes of multiple sites)
- C83.39 (diffuse large B-cell lymphoma, extranodal and solid organ sites)	- 200.00 (above) - 200.70 (above)
- C83.390 (primary central nervous system lymphoma); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>
- C83.398 (diffuse large B-cell lymphoma of <i>other</i> extranodal and solid organ sites); <i>new 2025</i>	
- C83.3A (in remission); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>
<i>C83.5 (lymphoblastic (diffuse) lymphoma...)</i>	<i>200.1 (lymphosarcoma...)</i>
- C83.50 (unspecified site)	- 200.10 (unspecified site, extranodal and solid organ sites)
- C83.51 (lymph nodes of head, face and neck)	- 200.11 (lymph nodes of head, face and neck)
- C83.52 (intrathoracic lymph nodes)	- 200.12 (intrathoracic lymph nodes)
- C83.53 (intra-abdominal lymph nodes)	- 200.13 (intra-abdominal lymph nodes)
- C83.54 (lymph nodes of axilla and upper limb)	- 200.14 (lymph nodes of axilla and upper limb)
- C83.55 (lymph nodes of inguinal region and lower limb)	- 200.15 (lymph nodes of inguinal region and lower limb)
- C83.56 (intrapelvic lymph nodes)	- 200.16 (intrapelvic lymph nodes)
- C83.57 (spleen)	- 200.17 (spleen)
- C83.58 (lymph nodes of multiple sites)	- 200.18 (lymph nodes of multiple sites)
- C83.59 (extranodal and solid organ site)	- 200.10 (above)
- C83.5A (in remission); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>
<i>C83.7 (Burkitt lymphoma...)</i>	<i>200.2 (Burkitt's tumor or lymphoma...)</i>
- C83.70 (unspecified site)	- 200.20 (unspecified site, extranodal and solid organ sites)
- C83.71 (lymph nodes of head, face and neck)	- 200.21 (lymph nodes of head, face and neck)
- C83.72 (intrathoracic lymph nodes)	- 200.22 (intrathoracic lymph nodes)



- C83.73 (intra-abdominal lymph nodes)	- 200.23 (intra-abdominal lymph nodes)
- C83.74 (lymph nodes of axilla and upper limb)	- 200.24 (lymph nodes of axilla and upper limb)
- C83.75 (lymph nodes of inguinal region and lower limb)	- 200.25 (lymph nodes of inguinal region and lower limb)
- C83.76 (intrapelvic lymph nodes)	- 200.26 (intrapelvic lymph nodes)
- C83.77 (spleen)	- 200.27 (spleen)
- C83.78 (lymph nodes of multiple sites)	- 200.28 (lymph nodes of multiple sites)
- C83.79 (extranodal and solid organ site)	- 200.20 (above)
- C83.7A (in remission); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>
<i>C83.8 (other non-follicular lymphoma...)</i>	<i>200.3 (marginal zone lymphoma...)</i> <i>200.5 (primary central nervous system lymphoma...)</i>
- C83.80 (unspecified site)	- 200.30 (unspecified site, extranodal and solid organ sites) - 200.50 (unspecified site, extranodal and solid organ sites)
- C83.81 (lymph nodes of head, face and neck)	- 200.31 (lymph nodes of head, face and neck) - 200.51 (lymph nodes of head, face and neck)
- C83.82 (intrathoracic lymph nodes)	- 200.32 (intrathoracic lymph nodes) - 200.52 (intrathoracic lymph nodes)
- C83.83 (intra-abdominal lymph nodes)	- 200.33 (intra-abdominal lymph nodes) - 200.53 (intra-abdominal lymph nodes)
- C83.84 (lymph nodes of axilla and upper limb)	- 200.34 (lymph nodes of axilla and upper limb) - 200.54 (lymph nodes of axilla and upper limb)
- C83.85 (lymph nodes of inguinal region and lower limb)	- 200.35 (lymph nodes of inguinal region and lower limb) - 200.55 (lymph nodes of inguinal region and lower limb)
- C83.86 (intrapelvic lymph nodes)	- 200.36 (intrapelvic lymph nodes) - 200.56 (intrapelvic lymph nodes)
- C83.87 (spleen)	- 200.37 (spleen) - 200.57 (spleen)

	- C83.88 (lymph nodes of multiple sites)	- 200.38 (lymph nodes of multiple sites) - 200.58 (lymph nodes of multiple sites)
	- C83.89 (extranodal and solid organ site)	- 200.30 (above) - 200.50 (above)
	- C83.8A (in remission); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>
	<i>C83.9 (non-follicular (diffuse) lymphoma, unspecified...)</i>	200.8[0-8] (above)
	- C83.90 (unspecified site)	
	- C83.91 (lymph nodes of head, face and neck)	
	- C83.92 (intrathoracic lymph nodes)	
	- C83.93 (intra-abdominal lymph nodes)	
	- C83.94 (lymph nodes of axilla and upper limb)	
	- C83.95 (lymph nodes of inguinal region and lower limb)	
	- C83.96 (intrapelvic lymph nodes)	
	- C83.97 (spleen)	
	- C83.98 (lymph nodes of multiple sites)	
	- C83.99 (extranodal and solid organ site)	
	- C83.9A (in remission); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>
Mature T/NK-cell lymphomas	<i>C84 (mature T/NK cell lymphoma)</i>	--
	<i>C84.0 (mycosis fungoides...)</i>	<i>202.1 (mycosis fungoides...)</i>
	- C84.00 (unspecified site)	- 202.10 (unspecified site, extranodal and solid organ sites)
	- C84.01 (lymph nodes of head, face and neck)	- 202.11 (lymph nodes of head, face and neck)
	- C84.02 (intrathoracic lymph nodes)	- 202.12 (intrathoracic lymph nodes)
	- C84.03 (intra-abdominal lymph nodes)	- 202.13 (intra-abdominal lymph nodes)
	- C84.04 (lymph nodes of axilla and upper limb)	- 202.14 (lymph nodes of axilla and upper limb)
	- C84.05 (lymph nodes of inguinal region and lower limb)	- 202.15 (lymph nodes of inguinal region and lower limb)
	- C84.06 (intrapelvic lymph nodes)	- 202.16 (intrapelvic lymph nodes)
	- C84.07 (spleen)	- 202.17 (spleen)

- C84.08 (lymph nodes of multiple sites)	- 202.18 (lymph nodes of multiple sites)
- C84.09 (extranodal and solid organ site)	- 202.10 (above)
- C84.0A (in remission); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>
<i>C84.1 (Sezary disease...)</i>	<i>202.2 (Sezary's disease...)</i>
- C84.10 (unspecified site)	- 202.20 (unspecified site, extranodal and solid organ sites)
- C84.11 (lymph nodes of head, face and neck)	- 202.21 (lymph nodes of head, face and neck)
- C84.12 (intrathoracic lymph nodes)	- 202.22 (intrathoracic lymph nodes)
- C84.13 (intra-abdominal lymph nodes)	- 202.23 (intra-abdominal lymph nodes)
- C84.14 (lymph nodes of axilla and upper limb)	- 202.24 (lymph nodes of axilla and upper limb)
- C84.15 (lymph nodes of inguinal region and lower limb)	- 202.25 (lymph nodes of inguinal region and lower limb)
- C84.16 (intrapelvic lymph nodes)	- 202.26 (intrapelvic lymph nodes)
- C84.17 (spleen)	- 202.27 (spleen)
- C84.18 (lymph nodes of multiple sites)	- 202.28 (lymph nodes of multiple sites)
- C84.19 (extranodal and solid organ site)	- 202.20 (above)
- C84.1A (in remission); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>
<i>C84.4 (peripheral T-cell lymphoma, not classified...)</i>	<i>202.7 (peripheral T cell lymphoma...)</i>
- C84.40 (unspecified site)	- 202.70 (unspecified site, extranodal and solid organ sites)
- C84.41 (lymph nodes of head, face and neck)	- 202.71 (lymph nodes of head, face and neck)
- C84.42 (intrathoracic lymph nodes)	- 202.72 (intrathoracic lymph nodes)
- C84.43 (intra-abdominal lymph nodes)	- 202.73 (intra-abdominal lymph nodes)
- C84.44 (lymph nodes of axilla and upper limb)	- 202.74 (lymph nodes of axilla and upper limb)
- C84.45 (lymph nodes of inguinal region and lower limb)	- 202.75 (lymph nodes of inguinal region and lower limb)
- C84.46 (intrapelvic lymph nodes)	- 202.76 (intrapelvic lymph nodes)
- C84.47 (spleen)	- 202.77 (spleen)
- C84.48 (lymph nodes of multiple sites)	- 202.78 (lymph nodes of multiple sites)
- C84.49 (extranodal and solid organ site)	- 202.70 (above)

- C84.4A (in remission); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>
<i>C84.6 (anaplastic large cell lymphoma, ALK positive...)</i>	<i>200.6 (anaplastic large cell lymphoma...)</i>
- C84.60 (unspecified site)	- 200.60 (unspecified site, extranodal and solid organ sites)
- C84.61 (lymph nodes of head, face and neck)	- 200.61 (lymph nodes of head, face and neck)
- C84.62 (intrathoracic lymph nodes)	- 200.62 (intrathoracic lymph nodes)
- C84.63 (intra-abdominal lymph nodes)	- 200.63 (intra-abdominal lymph nodes)
- C84.64 (lymph nodes of axilla and upper limb)	- 200.64 (lymph nodes of axilla and upper limb)
- C84.65 (lymph nodes of inguinal region and lower limb)	- 200.65 (lymph nodes of inguinal region and lower limb)
- C84.66 (intrapelvic lymph nodes)	- 200.66 (intrapelvic lymph nodes)
- C84.67 (spleen)	- 200.67 (spleen)
- C84.68 (lymph nodes of multiple sites)	- 200.68 (lymph nodes of multiple sites)
- C84.69 (extranodal and solid organ sites)	- 200.60 (above)
- C84.6A (in remission); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>
<i>C84.7 (anaplastic large cell lymphoma, ALK negative...)</i>	200.6[0-8] (above)
- C84.70 (unspecified site)	
- C84.71 (lymph nodes of head, face and neck)	
- C84.72 (intrathoracic lymph nodes)	
- C84.73 (intra-abdominal lymph nodes)	
- C84.74 (lymph nodes of axilla and upper limb)	
- C84.75 (lymph nodes of inguinal region and lower limb)	
- C84.76 (intrapelvic lymph nodes)	
- C84.77 (spleen)	
- C84.78 (lymph nodes of multiple sites)	
- C84.79 (extranodal and solid organ sites)	
- C84.7A (breast); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>
- C84.7B (in remission); <i>new 2025</i>	

<i>C84.A (cutaneous T-cell lymphoma, unspecified...)</i>	202.8[0-8] (above)
- C84.A0 (unspecified site)	
- C84.A1 (lymph nodes of head, face and neck)	
- C84.A2 (intrathoracic lymph nodes)	
- C84.A3 (intra-abdominal lymph nodes)	
- C84.A4 (lymph nodes of axilla and upper limb)	
- C84.A5 (lymph nodes of inguinal region and lower limb)	
- C84.A6 (intrapelvic lymph nodes)	
- C84.A7 (spleen)	
- C84.A8 (lymph nodes of multiple sites)	
- C84.A9 (extranodal and solid organ sites)	
- C84.AA (in remission); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>
<i>C84.Z (other mature T/NK cell lymphomas...)</i>	202.8[0-8] (above)
- C84.Z0 (unspecified site)	
- C84.Z1 (lymph nodes of head, face and neck)	
- C84.Z2 (intrathoracic lymph nodes)	
- C84.Z3 (intra-abdominal lymph nodes)	
- C84.Z4 (lymph nodes of axilla and upper limb)	
- C84.Z5 (lymph nodes of inguinal region and lower limb)	
- C84.Z6 (intrapelvic lymph nodes)	
- C84.Z7 (spleen)	
- C84.Z8 (lymph nodes of multiple sites)	
- C84.Z9 (extranodal and solid organ sites)	
- C84.ZA (in remission); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>
<i>C84.9 (mature T/NK cell lymphomas, unspecified...)</i>	202.8[0-8] (above)
- C84.90 (unspecified site)	

	- C84.91 (lymph nodes of head, face and neck)	
	- C84.92 (intrathoracic lymph nodes)	
	- C84.93 (intra-abdominal lymph nodes)	
	- C84.94 (lymph nodes of axilla and upper limb)	
	- C84.95 (lymph nodes of inguinal region and lower limb)	
	- C84.96 (intrapelvic lymph nodes)	
	- C84.97 (spleen)	
	- C84.98 (lymph nodes of multiple sites)	
	- C84.99 (extranodal and solid organ sites)	
	- C84.9A (in remission); <i>new 2025</i>	
		<i>No data available to convert ICD10 codes added after 2018.</i>
Specified and unspecified non-Hodgkin lymphomas	<i>C85 (other specified and unspecified types of non-Hodgkin lymphoma)</i>	202.8[0-8] (above)
	<i>C85.1 (unspecified B-cell lymphoma...)</i>	
	- C85.10 (unspecified site)	
	- C85.11 (lymph nodes of head, face and neck)	
	- C85.12 (intrathoracic lymph nodes)	
	- C85.13 (intra-abdominal lymph nodes)	
	- C85.14 (lymph nodes of axilla and upper limb)	
	- C85.15 (lymph nodes of inguinal region and lower limb)	
	- C85.16 (intrapelvic lymph nodes)	
	- C85.17 (spleen)	
	- C85.18 (lymph nodes of multiple sites)	
	- C85.19 (extranodal and solid organ sites)	
	- C85.1A (in remission); <i>new 2025</i>	
	<i>C85.2 (mediastinal (thymic) large B-cell lymphoma...)</i>	
	- C85.20 (unspecified site)	
	- C85.21 (lymph nodes of head, face and neck)	
		<i>No data available to convert ICD10 codes added after 2018.</i>
		202.7[0-8] (above)
		202.8[0-8] (above)



- C85.22 (intrathoracic lymph nodes)	
- C85.23 (intra-abdominal lymph nodes)	
- C85.24 (lymph nodes of axilla and upper limb)	
- C85.25 (lymph nodes of inguinal region and lower limb)	
- C85.26 (intrapelvic lymph nodes)	
- C85.27 (spleen)	
- C85.28 (lymph nodes of multiple sites)	
- C85.29 (extranodal and solid organ sites)	
- C85.2A (in remission); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>
<i>C85.8 (other specified types of non-Hodgkin lymphoma...)</i>	202.8[0-8] (above)
- C85.80 (unspecified site)	
- C85.81 (lymph nodes of head, face and neck)	
- C85.82 (intrathoracic lymph nodes)	
- C85.83 (intra-abdominal lymph nodes)	
- C85.84 (lymph nodes of axilla and upper limb)	
- C85.85 (lymph nodes of inguinal region and lower limb)	
- C85.86 (intrapelvic lymph nodes)	
- C85.87 (spleen)	
- C85.88 (lymph nodes of multiple sites)	
- C85.89 (extranodal and solid organ sites)	
- C85.8A (in remission); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>
<i>C85.9 (non-Hodgkin lymphoma, unspecified...)</i>	202.8[0-8] (above)
- C85.90 (unspecified site)	
- C85.91 (lymph nodes of head, face and neck)	
- C85.92 (intrathoracic lymph nodes)	
- C85.93 (intra-abdominal lymph nodes)	

	- C85.94 (lymph nodes of axilla and upper limb)	
	- C85.95 (lymph nodes of inguinal region and lower limb)	
	- C85.96 (intrapelvic lymph nodes)	
	- C85.97 (spleen)	
	- C85.98 (lymph nodes of multiple sites)	
	- C85.99 (extranodal and solid organ sites)	
	- C85.9A (in remission); <i>new 2025</i>	<i>No data available to convert ICD10 codes added after 2018.</i>
Other specified types of T/NK-cell lymphoma	<i>C86 (other specified types of T/NK-cell lymphoma)</i>	202.8[0-8] (above)
	- C86.0 (extranodal NK/T-cell lymphoma, nasal type)	<i>No data available to convert ICD10 codes added after 2018.</i>
	- C86.00 (not having achieved remission); <i>new 2025</i>	
	- C86.01 (in remission); <i>new 2025</i>	
	- C86.1 (hepatosplenic T-cell lymphoma)	
	- C86.10 (not having achieved remission); <i>new 2025</i>	
	- C86.11 (in remission); <i>new 2025</i>	
	- C86.2 (enteropathy-type, intestinal, T-cell lymphoma)	
	- C86.20 (not having achieved remission); <i>new 2025</i>	
	- C86.21 (in remission); <i>new 2025</i>	
	- C86.3 (subcutaneous panniculitis-like T-cell lymphoma)	
	- C86.30 (not having achieved remission); <i>new 2025</i>	
	- C86.31 (in remission); <i>new 2025</i>	
	- C86.4 (blastic NK-cell lymphoma)	
	- C86.40 (not having achieved remission); <i>new 2025</i>	
	- C86.41 (in remission); <i>new 2025</i>	
	- C86.5 (angioimmunoblastic T-cell lymphoma)	



	<ul style="list-style-type: none"> <li>- C86.50 (not having achieved remission); <i>new 2025</i></li> </ul>	
	<ul style="list-style-type: none"> <li>- C86.51 (in remission); <i>new 2025</i></li> </ul>	
	<ul style="list-style-type: none"> <li>- C86.6 (primary cutaneous CD30-positive T-cell proliferations)</li> </ul>	
	<ul style="list-style-type: none"> <li>- C86.60 (not having achieved remission); <i>new 2025</i></li> </ul>	
	<ul style="list-style-type: none"> <li>- C86.61 (in remission); <i>new 2025</i></li> </ul>	
Malignant immune-proliferative diseases and other B-cell lymphomas	<p><i>C88 (malignant immunoproliferative diseases and certain other B-cell lymphomas)</i></p> <ul style="list-style-type: none"> <li>- C88.0 (Waldenstrom macroglobulinemia)</li> <li>- C88.00 (not having achieved remission); <i>new 2025</i></li> <li>- C88.01 (in remission); <i>new 2025</i></li> <li>- C88.2 (heavy chain disease)</li> <li>- C88.20 (not having achieved remission); <i>new 2025</i></li> <li>- C88.11 (in remission); <i>new 2025</i></li> <li>- C88.3 (immunoproliferative small intestinal disease)</li> <li>- C88.30 (not having achieved remission); <i>new 2025</i></li> <li>- C88.31 (in remission); <i>new 2025</i></li> <li>- C88.4 (extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [ MALT-lymphoma])</li> <li>- C88.40 (not having achieved remission); <i>new 2025</i></li> <li>- C88.41 (in remission); <i>new 2025</i></li> </ul>	<p>200.30 (above)</p> <p>273.3 (macroglobulinemia)</p> <p><i>No data available to convert ICD10 codes added after 2018.</i></p>

Procedures	ICD-10-CM Codes	ICD-9-CM Codes
Related treatment procedures	Z51.0 (encounter for antineoplastic radiation therapy)	V58.0 (radiotherapy)
(Radiotherapy, chemotherapy, immunotherapy)	Z51.1 (encounter for antineoplastic chemotherapy and immunotherapy)	V58.1 (encounter for chemotherapy and immunotherapy for neoplastic conditions)
		(continued on next page)

	- Z51.11 (encounter for antineoplastic chemotherapy)	- V58.11 (encounter for antineoplastic chemotherapy)
	- Z51.12 (encounter for antineoplastic immunotherapy)	- V58.12 (encounter for antineoplastic immunotherapy)

## Development and Revisions

- In 2024, the DHA HSE cancer surveillance SubWG evaluated and expanded the list of cancers in the AFHSD cancer report to include breast (female), bladder, brain, cervical, colorectal, kidney (renal), leukemia, liver (hepatic), lung/bronchial, non-Hodgkin lymphoma, ovarian, pancreatic, prostate, stomach (gastric) and testicular cancer.
- In a 2019 *Monthly Surveillance Medical Report (MSMR)* article, analysis of the AFHSD standard oncology case revealed the definition had a high positive predictive value (PPV) for capturing cases of common cancers, (e.g., breast, prostate, testicular), and a low-to-moderate PPV for rarer cancers, (e.g., gallbladder, intestinal, laryngeal). Analyses also revealed the case definition was less sensitive for identifying cancers of the brain and nervous system, lung and bronchus, bones and joints, and liver ( $PPV \leq 50$  percent); these cases often represented metastases rather than true incident cases. While the broad application of a single case definition may affect the sensitivity and specificity in varying ways for the individual cancers, the PPV for all the cancers included in the report are  $>70$  percent, and most have a  $PPV \geq 90$  percent.<sup>4</sup>
- In June of 2015 the case definition was updated to include ICD10 codes.
- The standard AFHSD oncology case definition was originally developed in 2011 by the Armed Forces Health Surveillance Center (AFHSC) in collaboration with a working group of subject matter experts from the Office of the Assistant Secretary of Defense for Health Affairs (ASDHA), the United States Army Public Health Command (USAPHC) and the United States Military Cancer Institute for a report on 10 different *invasive* cancers. The case definition was developed based on reviews of the ICD9 codes, the scientific literature and previous AFHSC analyses.

## Case Definition and Incidence Rule Rationale

- The definition and classifications used in this case definition are based on the World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues, Revised 4<sup>th</sup> edition.<sup>5</sup>
- In the 2019 *MSMR* article, cases of non-Hodgkin lymphoma identified using the standard AFHSD oncology case definition had a total PPV of 78.1 percent [CI 71.3-83.9]: female 84.2 percent [CI 60.4-96.6], male 77.4 percent [CI 70.1-83.6], among a subset of active component and retired officers.<sup>4</sup>
- The case finding criteria of *three or more outpatient medical encounters, within a 90-day period*, is used to identify cases that do not meet the other criteria in the definition. Exploratory analysis of Defense Medical Surveillance System (DMSS) data revealed this criterion yielded optimal specificity.<sup>6</sup>

<sup>4</sup> Webber, B, Rogers, A, Pathak, S, Robbins, A. Positive Predictive Value of an Algorithm Used for Cancer Surveillance in the U.S. Armed Forces. *MSMR* 2019; 26(12):18-23

<sup>5</sup> Swerdlow, S. H., Campo, E., Harris, N. L., Jaffe, E. S., Pileri, S., Stein, H., & Thiele, J. (2017). *WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues* (4<sup>th</sup> ed., Vol. 2). International Agency for Research on Cancer.

<sup>6</sup> Detailed information on these analyses is available through AFHSD; reference DMSS Requests #R230308, #R230378 and #R240009.



- A period of 90 days allows for the likelihood that “true” cases of non-Hodgkin lymphoma will have second and third encounters within that timeframe. The timeframe is based on the following standards of care: (1) following a biopsy of a clinically suspicious lymph node, the average time to obtain a pathology report and definitive diagnosis is 1-3 weeks; (2) individuals whose biopsy results are positive non-Hodgkin lymphoma are likely to have a follow-up visit for treatment within 4 weeks of a definitive diagnosis; and (3) individuals are likely to have follow-up visits to monitor clinical indicators of disease within the 90-day timeframe.<sup>7</sup>
- For outpatient encounters, the incident date is considered the first of the three encounters occurring within the 90-day period, (e.g., if an individual has four non-Hodgkin lymphoma codes on 1-Jan-12, 1-Dec-15, 8-Dec-15, and 15-Dec-15, the incident date would be 1-Dec-15; 1-Jan-12 would be considered a screening encounter and dropped).
- To maintain consistency with the standard AFHSD methodology for surveillance of invasive cancers, AFHSD uses a *once per lifetime* incidence rule. The workgroup recognizes individuals, may be considered disease free after treatment or after an extended period of time, (e.g., 5 years), with no clinical evidence of disease. Individuals who develop a recurrence after being disease free could, theoretically, be counted as a new incident case. However, for surveillance of cancer using administrative, (i.e., billing), data, it is difficult to identify individuals who are disease free after treatment.

#### *Code Set Determination and Rationale*

- In June 2024, the DHA HSE cancer surveillance SubWG, in consultation with oncology experts at the DHA, reviewed the ICD10 C88.x and C96.x series of codes included in the existing code set and codes previously excluded by the Surveillance Methods and Standard (SMS) working group. The workgroup noted Weber, *et. al.* did not include ICD10 C88.x in the code set used for analyses in the 2019 *MSMR* article.<sup>5</sup> Based on expert consensus opinion and chart review, the workgroup determined C88.[0-4] should be included in the code set as these conditions are considered NHL or variants of NHL. The following codes were excluded from the code set. A brief rationale is included in the table.

ICD-10-CM Codes	ICD-9-CM Codes	Rationale
C88.8x (other malignant immunoproliferative diseases...[0] not having achieved remission, [1] in remission)	203.80 (other immunoproliferative neoplasm, without mention of having achieved remission)	Codes are infrequently used and too non-specific. Inclusion may result in too many false positive cases. Chart review revealed codes are used early on in the work up of patients and may or may not result in a more specific diagnosis.
C88.9x (malignant immunoproliferative disease, unspecified...[0] not having achieved remission, [1] in remission)	203.81 (other immunoproliferative neoplasms, in remission)	
C91.4 (hairy cell leukemia)	202.4x (leukemic reticuloendotheliosis)	Condition not considered NHL; historically included in the NHL category due to similarities in treatment.

*(continued on next page)*

<sup>7</sup> Non-Hodgkin Lymphoma. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2023. <https://www.nccn.org/guidelines/recently-published-guidelines>; Accessed March 2025.



C96 (other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue)	202 (other malignant neoplasms of lymphoid and histiocytic tissue)	Conditions are not considered NHL.
C96.0 (multifocal and multisystemic [disseminated] Langerhans-cell histiocytosis)	202.5x (Letterer-Siwe disease)	
C96.2x (malignant mast cell tumor...[0] unspecified, [1] aggressive systemic mastocytosis, [2] mast cell sarcoma, [9] other malignant mast cell neoplasm)	202.6x (malignant mast cell tumors)	
C96.4 (sarcoma of dendritic cells, accessory cells)	202.9x (other and unspecified malignant neoplasm of lymphoid and histiocytic tissue, unspecified site, extranodal and solid organ sites)	
C96.5 (multifocal and unisystemic Langerhans-cell histiocytosis)	277.89 (other specified disorders of metabolism)	
C96.6 (unifocal Langerhans-cell histiocytosis)		
C96.A (histiocytic sarcoma)	202.3x (malignant histiocytosis)	
C96.Z (other specified malignant neoplasm of lymphoid, hematopoietic and related tissue)	202.9x (above)	Likely used for conditions that are not NHL.  Codes were included in code set for NHL prior to 2024.
C96.9 (malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified)		

- Procedure codes (ICD10 and CPT) indicating surgical treatment of individual cancers such as hysterectomy, mastectomy, prostatectomy, and other procedures unique to certain types of cancers are not included in the code set. While procedure codes may increase the specificity of case finding criteria in select circumstances, analyses can be labor intensive and the effort does not necessarily guarantee a better case definition, (i.e., the definition may still identify false positive cases).
- *Screening for disease* codes ICD10 Z12.xx / ICD9 V76.xx (encounter for screening for malignant neoplasms) are not included in the code set. Screening codes are used for “testing for disease or disease precursors in seemingly well individuals so that early detection and treatment can be provided for those who test positive for the disease, (e.g., screening mammogram).”<sup>8</sup> They would not be used for follow-up medical encounters of a specific disease.
- *Personal history of malignant neoplasms* (ICD10 Z85.xx) codes are not included in the code set. While these codes may be beneficial for identifying individuals with a history of cancer, analysis of administrative data reveal these codes lack the specificity to count incident cancer cases and are inconsistently used by providers.<sup>9</sup> Given these findings, the AFHSD does not use personal history

<sup>8</sup> ICD-10-CM Official Guidelines for Coding and Reporting. FY 2022–Updated April 1, 2022. (October 1, 2021–September 30, 2022. <https://stacks.cdc.gov/view/cdc/126426>. Accessed March 2025.

<sup>9</sup> Analysis performed by the Defense Centers of Public Health-Dayton. Encounters with at least one Z85.x code in any diagnostic position (dx1- dx20) were pulled from Comprehensive Ambulatory Professional Encounter Records (CAPER) and Standard Inpatient Data Records (SIDR) for all Tri-Service beneficiaries between October 2016 and March 2024. A total of 546,962 encounters were identified. Of these, 68,395 (13%) had at least one neoplasm diagnosis (ICD10 C00-D49). With administrative data, there is no way to determine if the neoplasm codes refer to a



codes to exclude prevalent cases, (i.e., individuals with a history of cancer), nor to identify individuals who are disease free after treatment.

Personal history codes are intended to be used by providers for individuals who have a history of cancer *and* documented evidence in the medical record that the malignancy has been “excised or eradicated and all treatment is complete.” They are not used for a “self-reported” history of malignancy, and they should be used in conjunction with ICD10 codes for follow-up visits (Z08- encounter for follow-up examination after completed treatment for a malignant neoplasm), aftercare visits (Z51.0 - encounter for antineoplastic radiation therapy; Z51.1- encounter for antineoplastic chemotherapy and immunotherapy), and screening visits (Z12 - encounter for screening for malignant neoplasms).<sup>10</sup>

## Reports

The AFHSD reports on non-Hodgkin lymphoma in the following reports:

- Periodic *MSMR* articles.

## Review

Mar 2025	Case definition reviewed and updated by the DHA HSE cancer surveillance SubWG; approved by the AFHSD SMS working group.
May 2018	Case definition reviewed and updated by the Armed Forces Health Surveillance Branch (AFHSB) SMS working group.
June 2017	Case definition reviewed and updated by the AFHSB SMS working group.
June 2013	Case definition reviewed and adopted by the AFHSC SMS working group.
June 2012	Case definition developed and adopted by the AFHSC <i>MSMR</i> staff.

## Comments

None

resolved malignancy or a new cancer diagnosis. Records with conjunction codes for follow-up (Z08), aftercare (Z51.[0.1]) and screening (Z12) were queried: 420,236 (77%) had no conjunction codes in any diagnostic position suggesting providers use personal history codes independent of the purpose of the visit and potentially inconsistently.

<sup>10</sup> Bredehoeft, Emily. Clear Up Confusion as to When Cancer Becomes “History Of.” American Academy of Professional Coders (AAPC). <https://www.aapc.com/blog/40016-clear-up-confusion-as-to-when-cancer-becomes-history-of/>. Accessed March 2025.

